Kruppel-Benzeri Faktör (Klf) Ailesinin Kanser ile İlişkisi
Özet
Krüppel-benzeri faktör (KLF) ailesi, hücrelerin çoğalması, farklılaşması, büyümesi ve sağkalımı gibi kritik biyolojik süreçleri ve fizyolojik sistemleri düzenleyen 17 üyeli bir transkripsiyonel düzenleyici grubudur. Bu çalışma, KLF üyelerinin kanser gelişimi, ilerlemesi ve metastazı üzerindeki çok yönlü ve karmaşık rollerine ışık tutmaktadır. KLF proteinleri, doku türüne ve kanserin evresine bağlı olarak ya tümör baskılayıcı ya da onkogen (tümör oluşumunu destekleyen) olarak işlev görürler. Örneğin; KLF1 rahim ağzı ve kolorektal kanserlerde artarak metastazı desteklerken, KLF2 pankreas ve hepatoselüler kanserlerde tümör büyümesini ve göçünü engelleyen bir baskılayıcıdır. KLF4 ve KLF9 genel olarak rahim ağzı, mide, pankreas ve meme kanserlerinde tümör hücre çoğalmasını engelleyip apoptozu (programlı hücre ölümü) uyarırken; KLF5 mesane, mide ve endometriyum kanserlerinde onkojenik rol oynayarak hücre göçünü arttırır. Benzer şekilde KLF7 ve KLF11 glioma gibi agresif tümörlerde sağkalım oranını düşüren onkojenik etkiler gösterirken, KLF14 ve KLF15 akciğer ile mide kanserlerinde down-regüle (azalmış) olarak kötü prognozla ilişkilendirilir. KLF17 ise meme ve akciğer kanserlerinde metastazı negatif düzenleyen kritik bir faktördür. Sonuç olarak, spesifik bir KLF üyesinin artışı veya azalışı, farklı kanser türlerinde tamamen zıt etkiler yaratabilmekte, bu da KLF ailesini kanser tanısı, prognozu ve hedefe yönelik tedaviler için kritik birer biyobelirteç haline getirmektedir.
The Kruppel-like factor (KLF) family is a 17-member group of transcriptional regulators that modulate critical biological processes, physiological systems, cell proliferation, differentiation, growth, and survival. This study elucidates the multifaceted and complex roles of KLF members in cancer development, progression, and metastasis. KLF proteins function either as tumor suppressors or oncogenes depending on the tissue type and cancer stage. For instance, KLF1 is elevated in cervical and colorectal cancers to promote metastasis, whereas KLF2 acts as a suppressor inhibiting tumor growth and migration in pancreatic and hepatocellular cancers. KLF4 and KLF9 generally inhibit tumor cell proliferation and induce apoptosis in cervical, gastric, pancreatic, and breast cancers, while KLF5 plays an oncogenic role in bladder, gastric, and endometrial cancers by increasing cell migration. Similarly, KLF7 and KLF11 exhibit oncogenic effects that reduce survival rates in aggressive tumors like glioma, whereas KLF14 and KLF15 are downregulated in lung and gastric cancers, correlating with poor prognosis. KLF17 serves as a critical factor that negatively regulates metastasis in breast and lung cancers. Consequently, the upregulation or downregulation of a specific KLF member can induce entirely opposing effects across different cancer types, rendering the KLF family vital biomarkers for cancer diagnosis, prognosis, and targeted therapies.
Referanslar
McConnell BB, Yang VW. Mammalian Kruppel-like factors in health and diseases. Physiol Rev. 2010;90(4):1337-1381.
Tetreault MP, Yang Y, Katz JP. Kruppel-like factors in cancer. Nat Rev Cancer. 2013;13(10):701-713.
Zhu B, Liu Q, Han Q, et al. Downregulation of Kruppellike factor 1 inhibits the metastasis and invasion of cervical cancer cells. Mol Med Rep. 2018;18(4):3932-3940.
Huang Z, He H, Qiu F, et al. Expression and Prognosis Value of the KLF Family Members in Colorectal Cancer. J Oncol. 2022;2022:6571272.
Zhang D, Dai Y, Cai Y, et al. KLF2 is downregulated in pancreatic ductal adenocarcinoma and inhibits the growth and migration of cancer cells. Tumour Biol. 2016;37(3):3425-3431.
Chen Y, Yang L. FBXL19-AS1 aggravates the progression of hepatocellular cancer by downregulating KLF2. JBUON. 2021;26(2241-6293 (Electronic)):1333-1339.
Yuedi D, Houbao L, Pinxiang L, et al. KLF2 induces the senescence of pancreatic cancer cells by cooperating with FOXO4 to upregulate p21. Exp Cell Res. 2020;388(1):111784.
Sachdeva M, Dodd RD, Huang Z, et al. Epigenetic silencing of Kruppel like factor-3 increases expression of pro-metastatic miR-182. Cancer Lett. 2015;369(1):202-211.
Wang R, Xu J, Xu J, et al. MiR-326/Sp1/KLF3: A novel regulatory axis in lung cancer progression. Cell Prolif. 2019;52(2):e12551.
Wang X, Jiang Z, Zhang Y, et al. RNA sequencing analysis reveals protective role of kruppel-like factor 3 in colorectal cancer. (1949-2553 (Electronic)).
Yang W-T, Zheng P-S. Krüppel-like factor 4 functions as a tumor suppressor in cervical carcinoma. Cancer. 2012;118(15):3691-3702.
Zhao R, Liu Z, Xu W, et al. Helicobacter pylori infection leads to KLF4 inactivation in gastric cancer through a TET1‐mediated DNA methylation mechanism. Cancer Medicine. 2020;9(7):2551-2563.
Yan C, Yu J, Liu Y, et al. MiR-32 promotes gastric carcinoma tumorigenesis by targeting Kruppel-like factor 4. Biochemical and Biophysical Research Communications. 2015;467(4):913-920.
Rong Z, Luo Z, Zhang J, et al. GINS complex subunit 4, a prognostic biomarker and reversely mediated by Krüppel‐like factor 4, promotes the growth of colorectal cancer. Cancer Science. 2020;111(4):1203-1217.
Kojima J, Kubota K, Moritake T, et al. The krüppel-like factor5 (KLF5) regulates uterine endometrial cancer proliferation and migration. Gynecologic Oncology. 2019;154:101.
He P, Yang JW, Yang VW, et al. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice. Gastroenterology. 2018;154(5):1494-1508.e1413.
Yang D, Chen W, Zhang C, et al. KLF5 Is a Positive Regulator of Cell Proliferation in Gastric Cancer and Correlates with More Aggressive Disease. Journal of the American College of Surgeons. 2017;225(4):S193.
Du C, Gao Y, Xu S, et al. KLF5 promotes cell migration by up-regulating FYN in bladder cancer cells. FEBS Letters. 2016;590(3):408-418.
Takagi Y, Sakai N, Yoshitomi H, et al. High expression of Krüppel‐like factor 5 is associated with poor prognosis in patients with colorectal cancer. Cancer Science. 2020;111(6):2078-2092.
Dong Z, Yang L, Lai D. KLF5 strengthens drug resistance of ovarian cancer stem‐like cells by regulating survivin expression. Cell Proliferation. 2013;46(4):425-435.
Jia L, Zhou Z, Liang H, et al. KLF5 promotes breast cancer proliferation, migration and invasion in part by upregulating the transcription of TNFAIP2. Oncogene. 2015;35(16):2040-2051.
Li X, Zhang B, Wu Q, et al. Interruption of KLF5 acetylation converts its function from tumor suppressor to tumor promoter in prostate cancer cells. International Journal of Cancer. 2014:n/a-n/a.
Liu R, Shi P, Zhou Z, et al. Krüpple-like factor 5 is essential for mammary gland development and tumorigenesis. The Journal of Pathology. 2018;246(4):497-507.
Pang J, Li Z, Wang G, et al. miR‐214‐5p targets KLF5 and suppresses proliferation of human hepatocellular carcinoma cells. Journal of Cellular Biochemistry. 2018;120(2):1850-1859.
Wang Z, Qiu X, Zhang H, et al. KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma. Journal of Biochemical and Molecular Toxicology. 2020;34(5).
Ma J-B, Bai J-Y, Zhang H-B, et al. KLF5 inhibits STAT3 activity and tumor metastasis in prostate cancer by suppressing IGF1 transcription cooperatively with HDAC1. Cell Death & Disease. 2020;11(6).
Lei Z, Ma X, Li H, et al. Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis. Urologic Oncology: Seminars and Original Investigations. 2018;36(3):93.e23-93.e37.
Liu Z, Zhao C, Du S, et al. MiR-4262 inhibits the development of esophageal cancer by negatively regulating KLF6 level. Experimental and Molecular Pathology. 2020;115:104476.
Sangodkar J, Shi J, DiFeo A, et al. Functional role of the KLF6 tumour suppressor gene in gastric cancer. European Journal of Cancer. 2009;45(4):666-676.
Hanoun N, Bureau C, Diab T, et al. The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions. Journal of Hepatology. 2010;53(5):880-888.
Hong J, Wang X, Mei C, et al. Competitive regulation by transcription factors and DNA methylation in the bovine SIRT5 promoter: Roles of E2F4 and KLF6. Gene. 2019;684:39-46.
Chen C, Hyytinen E-R, Sun X, et al. Deletion, Mutation, and Loss of Expression of KLF6 in Human Prostate Cancer. The American Journal of Pathology. 2003;162(4):1349-1354.
Chen C, Hyytinen E-R, Sun X, et al. Deletion, Mutation, and Loss of Expression of KLF6 in Human Prostate Cancer. The American Journal of Pathology. 2003;162(4):1349-1354.
Guan F, Kang Z, Zhang J-T, et al. KLF7 promotes polyamine biosynthesis and glioma development through transcriptionally activating ASL. Biochemical and Biophysical Research Communications. 2019;514(1):51-57.
Zhao L, Zhang Y, Liu J, et al. miR-185 Inhibits the Proliferation and Invasion of Non-Small Cell Lung Cancer by Targeting KLF7. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 2019;27(9):1015-1023.
Niu R, Tang Y, Xi Y, et al. High Expression of Krüppel-like Factor 7 Indicates Unfavorable Clinical Outcomes in Patients with Lung Adenocarcinoma. Journal of Surgical Research. 2020;250:216-223.
Liu J, Zheng H, Ding Y, et al. The level of Krüppel-like factor 8 expression predicts prognosis and metastasis in various carcinomas. Medicine. 2019;98(18):e15519.
Wang X, Zheng M, Liu G, et al. Kruppel-Like Factor 8 Induces Epithelial to Mesenchymal Transition and Epithelial Cell Invasion. Cancer Research. 2007;67(15):7184-7193.
Li JC, Yang XR, Sun HX, et al. Up-regulation of Krüppel-Like Factor 8 Promotes Tumor Invasion and Indicates Poor Prognosis for Hepatocellular Carcinoma. Gastroenterology. 2010;139(6):2146-2157.e2112.
Zhang H, Sun L, Xiao X, et al. Krüppel‐like factor 8 contributes to hypoxia‐induced MDR in gastric cancer cells. Cancer Science. 2014;105(9):1109-1115.
Sun J, Wang B, Liu Y, et al. Transcription factor KLF9 suppresses the growth of hepatocellular carcinoma cells in vivo and positively regulates p53 expression. Cancer Letters. 2014;355(1):25-33.
Zhong Z, Zhou F, Wang D, et al. Expression of KLF9 in pancreatic cancer and its effects on the invasion, migration, apoptosis, cell cycle distribution, and proliferation of pancreatic cancer cell lines. Oncology Reports. 2018.
Huang S, Wang C, Yi Y, et al. Krüppel-like factor 9 inhibits glioma cell proliferation and tumorigenicity via downregulation of miR-21. Cancer Letters. 2015;356(2):547-555.
Bai X-Y, Li S, Wang M, et al. Krüppel-like factor 9 down-regulates matrix metalloproteinase 9 transcription and suppresses human breast cancer invasion. Cancer Letters. 2018;412:224-235.
Jiang Z, Xu Z, Hu i, et al. Expression of Krüppel-like factor 9 in breast cancer patients and its effect on prognosis. ONCOLOGY LETTERS. 2020;20 1311-1317.
Memon A, Lee W. KLF10 as a Tumor Suppressor Gene and Its TGF-β Signaling. Cancers. 2018;10(6):161.
Spittau G, Happel N, Behrendt M, et al. Tieg1/Klf10 is upregulated by NGF and attenuates cell cycle progression in the pheochromocytoma cell line PC12. Journal of Neuroscience Research. 2010:NA-NA.
Song K-D, Kim D-J, Lee JE, et al. KLF10, transforming growth factor-β-inducible early gene 1, acts as a tumor suppressor. Biochemical and Biophysical Research Communications. 2012;419(2):388-394.
Xi Z, Zhang R, Zhang F, et al. KLF11 Expression Predicts Poor Prognosis in Glioma Patients. Int J Gen Med. 2021;14:2923-2929.
Ji Q, Li Y, Zhao Q, et al. KLF11 promotes gastric cancer invasion and migration by increasing Twist1 expression. Neoplasma. 2019;66(1):92-100.
Lin L, Mahner S, Jeschke U, et al. The Distinct Roles of Transcriptional Factor KLF11 in Normal Cell Growth Regulation and Cancer as a Mediator of TGF-beta Signaling Pathway. Int J Mol Sci. 2020;21(8).
Ding L, Ding Y, Kong X, et al. Dysregulation of Krüppel-like factor 12 in the development of endometrial cancer. Gynecologic Oncology. 2019;152(1):177-184.
Shen X, Hu Y, Jiang Y, et al. Krüppel-like factor 12 negatively regulates human endometrial stromal cell decidualization. Biochemical and Biophysical Research Communications. 2013;433(1):11-17.
He Z, Guo X, Tian S, et al. MicroRNA-137 reduces stemness features of pancreatic cancer cells by targeting KLF12. Journal of Experimental & Clinical Cancer Research. 2019;38(1).
Fernandez-Zapico ME, Billadeau DD, Urrutia R. KLF13 SUPPRESSES THE TRANSFORMING ACTIVITY OF K-RAS BY DIRECT DOWNREGULATION THE CYCLIN B GENE. Pancreas. 2004;29(4):360.
Gordon AR, Outram SV, Keramatipour M, et al. Splenomegaly and Modified Erythropoiesis in KLF13–/– Mice. Journal of Biological Chemistry. 2008;283(18):11897-11904.
Outram SV, Gordon AR, Hager-Theodorides AL, et al. KLF13 influences multiple stages of both B and T cell development. Cell Cycle. 2014;7(13):2047-2055.
Wu R, Yun Q, Zhang J, et al.
Downregulation of KLF13 through DNMT1-mediated hypermethylation promotes glioma cell proliferation and invasion
. OncoTargets and Therapy. 2019;Volume 12:1509-1520.Wang Q, Peng R, Wang B, et al. Transcription factor KLF13 inhibits AKT activation and suppresses the growth of prostate carcinoma cells. Cancer Biomarkers. 2018;22(3):533-541.
Zhang W, Hong S, Maniar KP, et al. KLF13 regulates the differentiation-dependent human papillomavirus life cycle in keratinocytes through STAT5 and IL-8. Oncogene. 2016;35(42):5565-5575.
Fan G, Sun L, Shan P, et al. Loss of KLF14 triggers centrosome amplification and tumorigenesis. Nature Communications. 2015;6(1).
Wu G, Yuan S, Chen Z, et al. The KLF14 Transcription Factor Regulates Glycolysis by Downregulating LDHB in Colorectal Cancer. International Journal of Biological Sciences. 2019;15(3):628-635.
Sun C, Ma P, Wang Y, et al. KLF15 Inhibits Cell Proliferation in Gastric Cancer Cells via Up-Regulating CDKN1A/p21 and CDKN1C/p57 Expression. Digestive Diseases and Sciences. 2017;62(6):1518-1526.
Wang X, He M, Li J, et al. KLF15 suppresses cell growth and predicts prognosis in lung adenocarcinoma. Biomedicine & Pharmacotherapy. 2018;106:672-677.
Yoda T, McNamara KM, Miki Y, et al. KLF15 in breast cancer: a novel tumor suppressor? Cell Oncol (Dordr). 2015;38(3):227-235.
Daftary GS, Lomberk GA, Buttar NS, et al. Detailed structural-functional analysis of the Kruppel-like factor 16 (KLF16) transcription factor reveals novel mechanisms for silencing Sp/KLF sites involved in metabolism and endocrinology. J Biol Chem. 2012;287(10):7010-7025.
Chen X, Li S, Ke Y, et al. KLF16 suppresses human glioma cell proliferation and tumourigenicity by targeting TFAM. Artificial Cells, Nanomedicine, and Biotechnology. 2018;46(sup1):608-615.
Bartolucci J, Verdugo FJ, González PL, et al. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure. Circulation Research. 2017;121(10):1192-1204.
Ali A, Ielciu I, Alkreathy HM, et al. KLF17 attenuates estrogen receptor α-mediated signaling by impeding ERα function on chromatin and determines response to endocrine therapy. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms. 2016;1859(7):883-895.
Gao SP, Sun HF, Li LD, et al. UHRF1 promotes breast cancer progression by suppressing KLF17 expression by hypermethylating its promoter. Am J Cancer Res. 2017;7(7):1554-1565.
Ismail IA, El-Sokkary GH, Saber SH. Low doses of Paclitaxel repress breast cancer invasion through DJ-1/KLF17 signalling pathway. Clinical and Experimental Pharmacology and Physiology. 2018;45(9):961-968.
Ismail IA, Kang HS, Lee HJ, et al. DJ-1 upregulates breast cancer cell invasion by repressing KLF17 expression. British Journal of Cancer. 2014;110(5):1298-1306.
El‐Sokkary GH, Ismail IA, Saber SH. Melatonin inhibits breast cancer cell invasion through modulating DJ‐1/KLF17/ID‐1 signaling pathway. Journal of Cellular Biochemistry. 2018;120(3):3945-3957.
Gumireddy K, Li A, Gimotty PA, et al. KLF17 is a negative regulator of epithelial–mesenchymal transition and metastasis in breast cancer. Nature Cell Biology. 2009;11(11):1297-1304.
Cai X-d, Zhou Y-b, Huang L-x, et al. Reduced expression of Krüppel-like factor 17 is related to tumor growth and poor prognosis in lung adenocarcinoma. Biochemical and Biophysical Research Communications. 2012;418(1):67-73.
